Current commercial dPCR platforms: technology and market review. (3rd April 2023)

• Record Type: Journal Article
• Authors: Tan, Li Ling; Loganathan, Nitin; Agarwalla, Sushama; Yang, Chun; Yuan, Weiyong; Zeng, Jasmine; Wu, Ruige; Wang, Wei; Duraiswamy, Suhanya
• Is Part Of: Critical reviews in biotechnology. Volume 43:Number 3(2023)
• Page Start: 433
• Page End: 464
• Publication Date: 2023-04-03
• Subjects: Digital PCR -- polymerase chain reaction -- equipment -- instrument -- real-time PCR -- QX100 -- QX200 -- QuantStudio; Biotechnology -- Periodicals; Biotechnology -- Periodicals; Review Literature -- Periodicals; Public Health -- Periodicals; Environment -- Periodicals; Industry -- Periodicals; Biotechnology; Review Literature; Public Health; Environment; Industry; 660.6
• DOI: 10.1080/07388551.2022.2037503
• Languages: English
• ISSNs: 0738-8551

Abstract

Abstract: Digital polymerase chain reaction (dPCR) technology has provided a new technique for molecular diagnostics, with superior advantages, such as higher sensitivity, precision, and specificity over quantitative real-time PCRs (qPCR). Eight companies have offered commercial dPCR instruments: Fluidigm Corporation, Bio-Rad, RainDance Technologies, Life Technologies, Qiagen, JN MedSys Clarity, Optolane, and Stilla Technologies Naica. This paper discusses the working principle of each offered dPCR device and compares the associated: technical aspects, usability, costs, and current applications of each dPCR device. Lastly, up-and-coming dPCR technologies are also presented, as anticipation of how the dPCR device landscape may likely morph in the next few years.